TY - JOUR
T1 - Regulatory T cells in the treatment of disease
AU - Sharabi, Amir
AU - Tsokos, Maria G.
AU - Ding, Ying
AU - Malek, Thomas R.
AU - Klatzmann, David
AU - Tsokos, George C.
N1 - Funding Information:
The authors’ work was supported by US National Institutes of Health (NIH) grants AI42269, R37AI49954, AI068787, AI085567 and AR064350 (G.C.T.) and R21-CA195334, R01-AI131648 and the Sylvester Comprehensive Cancer Center at the University of Miami (T.R.M.).
Publisher Copyright:
© 2018 Springer Nature Limited. All rights reserved.
PY - 2018/10/30
Y1 - 2018/10/30
N2 - Regulatory T (Treg) cells suppress inflammation and regulate immune system activity. In patients with systemic or organ-specific autoimmune diseases or those receiving transplanted organs, Treg cells are compromised. Approaches to strengthen Treg cell function, either by expanding them ex vivo and reinfusing them or by increasing the number or capacity of existing Treg cells, have entered clinical trials. Unlike the situation in autoimmunity, in patients with cancer, Treg cells limit the antitumour immune response and promote angiogenesis and tumour growth. Their immunosuppressive function may, in part, explain the failure of many immunotherapies in cancer. Strategies to reduce the function and/or number of Treg cells specifically in tumour sites are being investigated to promote antitumour immunity and regression. Here, we describe the current progress in modulating Treg cells in autoimmune disorders, transplantation and cancer.
AB - Regulatory T (Treg) cells suppress inflammation and regulate immune system activity. In patients with systemic or organ-specific autoimmune diseases or those receiving transplanted organs, Treg cells are compromised. Approaches to strengthen Treg cell function, either by expanding them ex vivo and reinfusing them or by increasing the number or capacity of existing Treg cells, have entered clinical trials. Unlike the situation in autoimmunity, in patients with cancer, Treg cells limit the antitumour immune response and promote angiogenesis and tumour growth. Their immunosuppressive function may, in part, explain the failure of many immunotherapies in cancer. Strategies to reduce the function and/or number of Treg cells specifically in tumour sites are being investigated to promote antitumour immunity and regression. Here, we describe the current progress in modulating Treg cells in autoimmune disorders, transplantation and cancer.
UR - http://www.scopus.com/inward/record.url?scp=85055990580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055990580&partnerID=8YFLogxK
U2 - 10.1038/nrd.2018.148
DO - 10.1038/nrd.2018.148
M3 - Review article
C2 - 30310234
AN - SCOPUS:85055990580
VL - 17
SP - 823
EP - 844
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
SN - 1474-1776
IS - 11
ER -